



Order ID 204187
 Provider Example Provider MD

Specimen
 Collected 08/20/2020
 Received 08/20/2020
Test Order
 Created 08/20/2020
 Reported 08/24/2020

Patient
Test, Vasculitis 1
 Gender - DOB Male - 01/01/2001
 Identifier Received
 Exagen ID 302583

AVISE VASCULITIS AAV

| | | |
|---------------------------------|-----------------------------------|--------------------------|
| AVISE VASCULITIS RESULT: | p-ANCA Positive >1:1280 | Anti-MPO Positive |
|---------------------------------|-----------------------------------|--------------------------|

ANCA by IFA Titer: >1:1280 Positive IFA:<1:20-Negative | ≥20 Positive

Pattern: Perinuclear (p-ANCA)

Positive ANCAs are useful in the diagnosis of small vessel vasculitis - granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. However, they can also be seen in connective tissue disease, IBD, some infections, malignancy, and as a reaction to drugs. Therefore, they should be interpreted with care in light of the clinical findings and workup.

| Vasculitis-Associated Analytes: | Value | Interpretation | Reference Range |
|---------------------------------|---------|----------------|----------------------------------|
| Anti-MPO IgG | >740 CU | Positive | CIA: <20-Negative ≥20-Positive |
| Anti-PR3 IgG | <2 CU | Negative | CIA: <20-Negative ≥20-Positive |
| Anti-GBM IgG | 3 CU | Negative | CIA: <20-Negative ≥20-Positive |

Test Method Description:

Results were obtained by NOVA Lite DAPI ANCA (Ethanol) and (Formalin) Kits indirect immunofluorescence assays for the qualitative detection semi-quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) of IgG isotypes in human serum by manual fluorescence microscopy or with NOVA View Automated Fluorescence Microscope. Chemiluminescent immunoassays (CIA) were used for the semi-quantitative detection of IgG anti-proteinase 3 (PR3) autoantibodies, IgG anti-myeloperoxidase (MPO) autoantibodies and IgG anti-glomerular basement membrane (GBM) autoantibodies in human serum or plasma on the Bio-Flash® instruments.

References:

Autoimm Rev (2016) 15:978; Am J Clin Pathol (1999) 111:507; Nature Reviews (2017) 13:683; Clin Chim Acta (2012) 413:719; Nephrolog Dial Transplant (2012) 27:243; Kidney Internatl (2017) 92:693; Curr Opin Nephrol Hypertens (2011) 20(3):290; BMJ (2020) 368:m421; Clin J Am Soc Nephrol (2017) 12:1162.



1261 Liberty Way, Vista CA 92081
 CLIA# 05D1075048
 CAP# 7201051 | NYSDOH PFI# 8369

Laboratory Directors:
 Richard Safrin, MD
 R. Harper Summers, MD

Provider Relations: 888.452.1522

AVISE and the AVISE and Exagen logos are registered trademarks of Exagen Inc. ©2020 All Rights Reserved

This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research. It has not been cleared or approved by the FDA. Exagen is regulated under CLIA as qualified to perform high-complexity testing.